Huntington's disease CAG trinucleotide repeats in pathologically confirmed post-mortem brains

CAG repeat expansion in the Huntington's disease gene (HD) was examined in postmortem brains from 310 clinically diagnosed and 15 ‘at risk’ individuals. Presence of an expanded CAG allele (>37 units) was the cause of the disorder in almost all cases (307 of 310). Despite a diversity of repor...

Full description

Bibliographic Details
Main Authors: Francesca Persichetti, Jayalakshmi Srinidhi, Lisa Kanaley, Pei Ge, Richard H. Myers, Kenneth D'Arrigo, Glenn T. Barnes, Marcy E. MacDonald, Jean-Paul Vonsattel, James F. Gusella, Edward D. Bird
Format: Article
Language:English
Published: Elsevier 1994-12-01
Series:Neurobiology of Disease
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S0969996184700192
id doaj-e9c2806463654e5ca90173fec7656a03
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Francesca Persichetti
Jayalakshmi Srinidhi
Lisa Kanaley
Pei Ge
Richard H. Myers
Kenneth D'Arrigo
Glenn T. Barnes
Marcy E. MacDonald
Jean-Paul Vonsattel
James F. Gusella
Edward D. Bird
spellingShingle Francesca Persichetti
Jayalakshmi Srinidhi
Lisa Kanaley
Pei Ge
Richard H. Myers
Kenneth D'Arrigo
Glenn T. Barnes
Marcy E. MacDonald
Jean-Paul Vonsattel
James F. Gusella
Edward D. Bird
Huntington's disease CAG trinucleotide repeats in pathologically confirmed post-mortem brains
Neurobiology of Disease
Huntington's disease
mutation
neuropathology
phenocopy
post-mortem brain
trinucleotide repeat
author_facet Francesca Persichetti
Jayalakshmi Srinidhi
Lisa Kanaley
Pei Ge
Richard H. Myers
Kenneth D'Arrigo
Glenn T. Barnes
Marcy E. MacDonald
Jean-Paul Vonsattel
James F. Gusella
Edward D. Bird
author_sort Francesca Persichetti
title Huntington's disease CAG trinucleotide repeats in pathologically confirmed post-mortem brains
title_short Huntington's disease CAG trinucleotide repeats in pathologically confirmed post-mortem brains
title_full Huntington's disease CAG trinucleotide repeats in pathologically confirmed post-mortem brains
title_fullStr Huntington's disease CAG trinucleotide repeats in pathologically confirmed post-mortem brains
title_full_unstemmed Huntington's disease CAG trinucleotide repeats in pathologically confirmed post-mortem brains
title_sort huntington's disease cag trinucleotide repeats in pathologically confirmed post-mortem brains
publisher Elsevier
series Neurobiology of Disease
issn 1095-953X
publishDate 1994-12-01
description CAG repeat expansion in the Huntington's disease gene (HD) was examined in postmortem brains from 310 clinically diagnosed and 15 ‘at risk’ individuals. Presence of an expanded CAG allele (>37 units) was the cause of the disorder in almost all cases (307 of 310). Despite a diversity of reporting clinicians, neurological and psychiatric onset and age at death all displayed significant inverse correlations with CAG number indicating that diagnosis of onset is reasonably accurate, and that most patients die from the disease and its complications. Neuronal changes before clinical onset are not detected by conventional microscopic examination as three out of 15 ‘at risk’ brains had an expanded CAG allele but no neuropathology. The cause of HD-like neuropathology in three exceptional brains from clinically diagnosed individuals is unclear. The disorder in these cases could be an HD phenocopy or result from alternative mutational mechanisms at theHDlocus.
topic Huntington's disease
mutation
neuropathology
phenocopy
post-mortem brain
trinucleotide repeat
url http://www.sciencedirect.com/science/article/pii/S0969996184700192
work_keys_str_mv AT francescapersichetti huntingtonsdiseasecagtrinucleotiderepeatsinpathologicallyconfirmedpostmortembrains
AT jayalakshmisrinidhi huntingtonsdiseasecagtrinucleotiderepeatsinpathologicallyconfirmedpostmortembrains
AT lisakanaley huntingtonsdiseasecagtrinucleotiderepeatsinpathologicallyconfirmedpostmortembrains
AT peige huntingtonsdiseasecagtrinucleotiderepeatsinpathologicallyconfirmedpostmortembrains
AT richardhmyers huntingtonsdiseasecagtrinucleotiderepeatsinpathologicallyconfirmedpostmortembrains
AT kennethdarrigo huntingtonsdiseasecagtrinucleotiderepeatsinpathologicallyconfirmedpostmortembrains
AT glenntbarnes huntingtonsdiseasecagtrinucleotiderepeatsinpathologicallyconfirmedpostmortembrains
AT marcyemacdonald huntingtonsdiseasecagtrinucleotiderepeatsinpathologicallyconfirmedpostmortembrains
AT jeanpaulvonsattel huntingtonsdiseasecagtrinucleotiderepeatsinpathologicallyconfirmedpostmortembrains
AT jamesfgusella huntingtonsdiseasecagtrinucleotiderepeatsinpathologicallyconfirmedpostmortembrains
AT edwarddbird huntingtonsdiseasecagtrinucleotiderepeatsinpathologicallyconfirmedpostmortembrains
_version_ 1724211505278222336
spelling doaj-e9c2806463654e5ca90173fec7656a032021-03-20T05:00:06ZengElsevierNeurobiology of Disease1095-953X1994-12-0113159166Huntington's disease CAG trinucleotide repeats in pathologically confirmed post-mortem brainsFrancesca Persichetti0Jayalakshmi Srinidhi1Lisa Kanaley2Pei Ge3Richard H. Myers4Kenneth D'Arrigo5Glenn T. Barnes6Marcy E. MacDonald7Jean-Paul Vonsattel8James F. Gusella9Edward D. Bird10Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown, MA, 02129; Brain Tissue Resource Center, McLean Hospital, Belmont, MA, 02178; Laboratory for Molecular Neuropathology, Massachusetts General Hospital, Charlestown, MA, 02129; Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, 02118; Department of Genetics, Harvard Medical School, Boston, MA, 02114, U.S.A.Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown, MA, 02129; Brain Tissue Resource Center, McLean Hospital, Belmont, MA, 02178; Laboratory for Molecular Neuropathology, Massachusetts General Hospital, Charlestown, MA, 02129; Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, 02118; Department of Genetics, Harvard Medical School, Boston, MA, 02114, U.S.A.Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown, MA, 02129; Brain Tissue Resource Center, McLean Hospital, Belmont, MA, 02178; Laboratory for Molecular Neuropathology, Massachusetts General Hospital, Charlestown, MA, 02129; Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, 02118; Department of Genetics, Harvard Medical School, Boston, MA, 02114, U.S.A.Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown, MA, 02129; Brain Tissue Resource Center, McLean Hospital, Belmont, MA, 02178; Laboratory for Molecular Neuropathology, Massachusetts General Hospital, Charlestown, MA, 02129; Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, 02118; Department of Genetics, Harvard Medical School, Boston, MA, 02114, U.S.A.Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown, MA, 02129; Brain Tissue Resource Center, McLean Hospital, Belmont, MA, 02178; Laboratory for Molecular Neuropathology, Massachusetts General Hospital, Charlestown, MA, 02129; Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, 02118; Department of Genetics, Harvard Medical School, Boston, MA, 02114, U.S.A.Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown, MA, 02129; Brain Tissue Resource Center, McLean Hospital, Belmont, MA, 02178; Laboratory for Molecular Neuropathology, Massachusetts General Hospital, Charlestown, MA, 02129; Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, 02118; Department of Genetics, Harvard Medical School, Boston, MA, 02114, U.S.A.Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown, MA, 02129; Brain Tissue Resource Center, McLean Hospital, Belmont, MA, 02178; Laboratory for Molecular Neuropathology, Massachusetts General Hospital, Charlestown, MA, 02129; Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, 02118; Department of Genetics, Harvard Medical School, Boston, MA, 02114, U.S.A.Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown, MA, 02129; Brain Tissue Resource Center, McLean Hospital, Belmont, MA, 02178; Laboratory for Molecular Neuropathology, Massachusetts General Hospital, Charlestown, MA, 02129; Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, 02118; Department of Genetics, Harvard Medical School, Boston, MA, 02114, U.S.A.Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown, MA, 02129; Brain Tissue Resource Center, McLean Hospital, Belmont, MA, 02178; Laboratory for Molecular Neuropathology, Massachusetts General Hospital, Charlestown, MA, 02129; Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, 02118; Department of Genetics, Harvard Medical School, Boston, MA, 02114, U.S.A.Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown, MA, 02129; Brain Tissue Resource Center, McLean Hospital, Belmont, MA, 02178; Laboratory for Molecular Neuropathology, Massachusetts General Hospital, Charlestown, MA, 02129; Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, 02118; Department of Genetics, Harvard Medical School, Boston, MA, 02114, U.S.A.Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown, MA, 02129; Brain Tissue Resource Center, McLean Hospital, Belmont, MA, 02178; Laboratory for Molecular Neuropathology, Massachusetts General Hospital, Charlestown, MA, 02129; Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, 02118; Department of Genetics, Harvard Medical School, Boston, MA, 02114, U.S.A.CAG repeat expansion in the Huntington's disease gene (HD) was examined in postmortem brains from 310 clinically diagnosed and 15 ‘at risk’ individuals. Presence of an expanded CAG allele (>37 units) was the cause of the disorder in almost all cases (307 of 310). Despite a diversity of reporting clinicians, neurological and psychiatric onset and age at death all displayed significant inverse correlations with CAG number indicating that diagnosis of onset is reasonably accurate, and that most patients die from the disease and its complications. Neuronal changes before clinical onset are not detected by conventional microscopic examination as three out of 15 ‘at risk’ brains had an expanded CAG allele but no neuropathology. The cause of HD-like neuropathology in three exceptional brains from clinically diagnosed individuals is unclear. The disorder in these cases could be an HD phenocopy or result from alternative mutational mechanisms at theHDlocus.http://www.sciencedirect.com/science/article/pii/S0969996184700192Huntington's diseasemutationneuropathologyphenocopypost-mortem braintrinucleotide repeat